Women's Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Correction

Bonefos receives FDA approvable letter as adjuvant treatment of breast cancer

Schering AG, Germany (SCH, SHR) announced that the U.S. Food and Drug

Administration (FDA) has issued an approvable letter for Bonefos

(clodronate), an oral non-amino bisphosphonate intended to reduce the

occurrence of bone metastases in the post-surgical (adjuvant) treatment of

breast cancer patients.

Berlex, Inc., Schering's U.S. affiliate, plans to request a meeting with

the FDA to discuss the information that is needed to obtain approval, and

will submit this information as quickly as...

• View Other Issues of Women's Health Weekly
  
• View Other NewsRx Publications